Loading stock data…
$23.55-0.73 (-3.01%)
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases.
Neurogene Inc. in the Healthcare sector is trading at $23.55 with a market capitalization of $530M. Wall Street consensus targets $77.88 (8 analysts), implying a +230.7% move over the next 12 months. The stock is currently 46% below its 52-week high of $43.66, remaining 14.6% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$36.67M↓ | -$33.35M↓ | -$27.53M↓ | -$23.80M↑ | -$26.08M |
| Net Income | -$34.49M↓ | -$30.93M↓ | -$24.73M↓ | -$20.95M↑ | -$22.02M |
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial ...